

The Australian Securities Exchange
Companies Announcements Office
SYDNEY

3 February 2012

Dear Sir/Madam

Extension of Public Offer Period

In accordance with the rights reserved under the Prospectus issued by Probiomics Limited (**Company**) and dated 21 December, 2011, the Company has decided to extend the Public Offer Period from Monday 6 February, 2012 at 4.00 p.m. (AEDST) to Monday 27 February, 2012 at 4.00 p.m. (AEDST).

Accordingly, the Company expects that the Public Offer will be completed in accordance with the following amended indicative timetable:

Event	Originally Proposed Date	Amended Date
Close of Public Offer Period	6 February, 2012	27 February, 2012
Issue of: <ul style="list-style-type: none"> • Public Offer Shares and Public Offer Options; • Bid Consideration, being Consolidated Probiomics Shares and Replacement Probiomics Options; and • Director Options and Probiomics Performance Executive Options 	19 March, 2012	Unchanged
Share Consolidation takes effect	21 March, 2012	Unchanged
Completion of dispatch of new holding statements to all Probiomics Securityholders to reflect: <ul style="list-style-type: none"> • issue of Probiomics Securities (see row 2 above); and • changes in holdings of Probiomics Securities as a result of the Share Consolidation 	28 March, 2012	Unchanged
Change in Probiomics' name to "Bioxyne Limited" becomes effective	30 March, 2012	Unchanged

As at the date of this announcement, it is not proposed to alter the date of any Event as stated in the “Important Dates” at the commencement of the Bidder’s Statement issued by the Company and dated 13 December, 2011, other than the closing date of the Public Offer Period.

However, the Company reserves the right to vary the date of any Event referred to in the “Important Dates”, including the date of any of the Events referred to in the table immediately above.

Yours sincerely,

A handwritten signature in black ink that reads 'Ashok Jairath' with a horizontal line underneath.

ASHOK JAIRATH
Company Secretary

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary
Tel: 02 9844 5422
Email ashok.jairath@probiomics.com.au

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.